{"title":"突尼斯人口中 toll-like receptor 4 变异对鼻咽癌风险和存活率的影响。","authors":"Arij Ben Chaaben, Imen Ayadi, Hejer Abaza, Olfa Baroudi, Hayet Douik, Latifa Harzallah, Jihen Bouassida, Wahid Bouckouaci, Fethi Guemira, Amani Mankai, Maher Kharrat, Ryad Tamouza","doi":"10.62438/tunismed.v102i2.4270","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The Toll-like receptor 4 (TLR4), an important member of the host's innate immune response, is coded by a polymorphic gene. This polymorphism could be a predisposing factor for NasoPharyngeal Carcinoma (NPC).</p><p><strong>Aim: </strong>To determine the association between TLR4 gene polymorphisms and the susceptibility to NPC in a cohort of Tunisian affected patients.</p><p><strong>Methods: </strong>Genomic DNAs from 245 unrelated patients affected by undifferentiated carcinoma type (UCNT) and 264 unrelated healthy controls were genotyped for the five single nucleotides polymorphisms (SNPs) of TLR4 locus (4434 A>G (rs1927914),7263 G>C (rs10759932), 6134 A>G(rs4986790), 8851C>T (rs 4986791), 5272 T>C(rs11536889), +8469 T>C (rs11536891)) by Taqman® 5'-nuclease assay.</p><p><strong>Results: </strong>Among all polymorphisms studied, only the rs4986790 G and rs4986791 T alleles were significantly more prevalent in patients' group than controls (45% vs. 38%; p=0.03; pc=0.06) and increased the risk of the NPC (OR=1.3, 95% CI=1.01-1.69). Also, we found that the frequency of the rs4986790 AA and rs4986791 TT genotypes was significantly higher in controls than in patients (25.7% vs 37%; p=0.006, pc=0.02) and conferred a protector factor in NPC (OR= 0.59, 95% CI= 0.39-0.87). Further, based on the Kaplan-Meier survival curve we observed also the positive effect ofrs1927914 AA genotype on a prognostic of NPC (p=0.006; pc=0.01).</p><p><strong>Conclusion: </strong>Our study demonstrated that impaired production of TLR4 seems to be a risk factor of NPC development but functional studies are needed to confirm these findings. As to rs1927914 AA appears to be a good biomarker for better survival in a patient with NPC.</p>","PeriodicalId":38818,"journal":{"name":"Tunisie Medicale","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11358798/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of toll-like receptor 4 variations on nasopharyngeal carcinoma risk and survival in tunisian population.\",\"authors\":\"Arij Ben Chaaben, Imen Ayadi, Hejer Abaza, Olfa Baroudi, Hayet Douik, Latifa Harzallah, Jihen Bouassida, Wahid Bouckouaci, Fethi Guemira, Amani Mankai, Maher Kharrat, Ryad Tamouza\",\"doi\":\"10.62438/tunismed.v102i2.4270\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The Toll-like receptor 4 (TLR4), an important member of the host's innate immune response, is coded by a polymorphic gene. This polymorphism could be a predisposing factor for NasoPharyngeal Carcinoma (NPC).</p><p><strong>Aim: </strong>To determine the association between TLR4 gene polymorphisms and the susceptibility to NPC in a cohort of Tunisian affected patients.</p><p><strong>Methods: </strong>Genomic DNAs from 245 unrelated patients affected by undifferentiated carcinoma type (UCNT) and 264 unrelated healthy controls were genotyped for the five single nucleotides polymorphisms (SNPs) of TLR4 locus (4434 A>G (rs1927914),7263 G>C (rs10759932), 6134 A>G(rs4986790), 8851C>T (rs 4986791), 5272 T>C(rs11536889), +8469 T>C (rs11536891)) by Taqman® 5'-nuclease assay.</p><p><strong>Results: </strong>Among all polymorphisms studied, only the rs4986790 G and rs4986791 T alleles were significantly more prevalent in patients' group than controls (45% vs. 38%; p=0.03; pc=0.06) and increased the risk of the NPC (OR=1.3, 95% CI=1.01-1.69). Also, we found that the frequency of the rs4986790 AA and rs4986791 TT genotypes was significantly higher in controls than in patients (25.7% vs 37%; p=0.006, pc=0.02) and conferred a protector factor in NPC (OR= 0.59, 95% CI= 0.39-0.87). Further, based on the Kaplan-Meier survival curve we observed also the positive effect ofrs1927914 AA genotype on a prognostic of NPC (p=0.006; pc=0.01).</p><p><strong>Conclusion: </strong>Our study demonstrated that impaired production of TLR4 seems to be a risk factor of NPC development but functional studies are needed to confirm these findings. As to rs1927914 AA appears to be a good biomarker for better survival in a patient with NPC.</p>\",\"PeriodicalId\":38818,\"journal\":{\"name\":\"Tunisie Medicale\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11358798/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tunisie Medicale\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.62438/tunismed.v102i2.4270\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tunisie Medicale","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62438/tunismed.v102i2.4270","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
简介Toll样受体4(TLR4)是宿主先天性免疫反应的重要成员,其编码基因具有多态性。目的:确定突尼斯受影响患者队列中 TLR4 基因多态性与鼻咽癌易感性之间的关联:方法:对 245 名无亲属关系的未分化癌(UCNT)患者和 264 名无亲属关系的健康对照者的基因组 DNA 进行基因分型,检测 TLR4 基因座的五个单核苷酸多态性(SNPs)(4434 A>G (rs1927914)、7263 G>C (rs10759932), 6134 A>G (rs4986790), 8851C>T (rs 4986791), 5272 T>C (rs11536889), +8469 T>C (rs11536891)).结果在所有研究的多态性中,只有 rs4986790 G 和 rs4986791 T 等位基因在患者组中的流行率明显高于对照组(45% 对 38%;P=0.03;Pc=0.06),并增加了患鼻咽癌的风险(OR=1.3,95% CI=1.01-1.69)。此外,我们还发现,rs4986790 AA 和 rs4986791 TT 基因型在对照组中的频率明显高于患者(25.7% vs 37%;p=0.006,pc=0.02),并赋予鼻咽癌保护因子(OR= 0.59,95% CI=0.39-0.87)。此外,根据 Kaplan-Meier 生存曲线,我们还观察到rs1927914 AA 基因型对鼻咽癌预后的积极影响(p=0.006;pc=0.01):我们的研究表明,TLR4生成障碍似乎是鼻咽癌发病的一个风险因素,但还需要功能研究来证实这些发现。至于 rs1927914 AA 似乎是提高鼻咽癌患者生存率的良好生物标志物。
Impact of toll-like receptor 4 variations on nasopharyngeal carcinoma risk and survival in tunisian population.
Introduction: The Toll-like receptor 4 (TLR4), an important member of the host's innate immune response, is coded by a polymorphic gene. This polymorphism could be a predisposing factor for NasoPharyngeal Carcinoma (NPC).
Aim: To determine the association between TLR4 gene polymorphisms and the susceptibility to NPC in a cohort of Tunisian affected patients.
Methods: Genomic DNAs from 245 unrelated patients affected by undifferentiated carcinoma type (UCNT) and 264 unrelated healthy controls were genotyped for the five single nucleotides polymorphisms (SNPs) of TLR4 locus (4434 A>G (rs1927914),7263 G>C (rs10759932), 6134 A>G(rs4986790), 8851C>T (rs 4986791), 5272 T>C(rs11536889), +8469 T>C (rs11536891)) by Taqman® 5'-nuclease assay.
Results: Among all polymorphisms studied, only the rs4986790 G and rs4986791 T alleles were significantly more prevalent in patients' group than controls (45% vs. 38%; p=0.03; pc=0.06) and increased the risk of the NPC (OR=1.3, 95% CI=1.01-1.69). Also, we found that the frequency of the rs4986790 AA and rs4986791 TT genotypes was significantly higher in controls than in patients (25.7% vs 37%; p=0.006, pc=0.02) and conferred a protector factor in NPC (OR= 0.59, 95% CI= 0.39-0.87). Further, based on the Kaplan-Meier survival curve we observed also the positive effect ofrs1927914 AA genotype on a prognostic of NPC (p=0.006; pc=0.01).
Conclusion: Our study demonstrated that impaired production of TLR4 seems to be a risk factor of NPC development but functional studies are needed to confirm these findings. As to rs1927914 AA appears to be a good biomarker for better survival in a patient with NPC.